CNTF-derived neurotrophic peptide mimetic · Fact sheet
P021 (P21)
Also known as P021 · Peptide 021
P021 is a CNTF-derived peptide mimetic studied in rodent aging and Alzheimer models. It has not established safe human neurogenesis, memory restoration or an anti-aging regimen.
What is P021 (P21)?
CNTF is ciliary neurotrophic factor. P021 is a designed mimetic rather than the full natural protein.
The shortened P21 label is not enough to confirm chemical identity; this entry concerns the P021 compound in the cited papers.
Benefits & claims
Interest centers on brain function and sleep, aging and cellular function. Biological activity does not itself establish a clinical treatment.
What the evidence supports
- An aged-rat study reported changes in learning and synaptic measures.
- A transgenic mouse study reported less tau-related pathology and selected cognitive effects.
- Mouse or rat neurogenesis findings do not prove regeneration of a human brain.
Research areas
- Experimental tissue and cellular responses
- Formulation-specific outcomes
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for P021 (P21). Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- CNTF is ciliary neurotrophic factor. P021 is a designed mimetic rather than the full natural protein.
Formulation differences
- The shortened P21 label is not enough to confirm chemical identity; this entry concerns the P021 compound in the cited papers.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Controlled human clinical outcomes for the exact substance
- Human exposure, pharmacokinetics and repeated-use safety
- Independent replication and formulation equivalence
Side effects & risks
- Human central-nervous-system, immune and long-term safety remain unestablished.
- A neurotrophic mechanism can have multiple tissue effects that are not captured by rodent cognitive tests.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Mostly animal or lab researchChronic rodent studies measured cognition, synaptic biology and disease-model pathology. These are not clinical human dementia trials.
Studies
Aged-rat cognition, neurogenesis and synaptic study.
Twelve-month transgenic mouse study.
Down-syndrome mouse-model developmental experiment.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
P021 (P21) has no FDA-approved therapeutic product. The cited experiments or cosmetic uses do not establish an approved human treatment.
Preclinical evidence; no FDA-approved product
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
- Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound.
- Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease.
- Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome.
Open questions
- Controlled human clinical outcomes for the exact substance
- Human exposure, pharmacokinetics and repeated-use safety
- Independent replication and formulation equivalence
Summary
Mouse or rat neurogenesis findings do not prove regeneration of a human brain.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedRescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound.
Aged-rat cognition, neurogenesis and synaptic study.
- pubmedDisease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease.
Twelve-month transgenic mouse study.
- pubmedEarly neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome.
Down-syndrome mouse-model developmental experiment.